Search details
1.
ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone.
Blood
; 143(23): 2401-2413, 2024 Jun 06.
Article
in English
| MEDLINE | ID: mdl-38427753
2.
The hepatic niche leads to aggressive natural killer cell leukemia proliferation through the transferrin-transferrin receptor 1 axis.
Blood
; 142(4): 352-364, 2023 07 27.
Article
in English
| MEDLINE | ID: mdl-37146246
3.
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Blood
; 139(6): 835-844, 2022 02 10.
Article
in English
| MEDLINE | ID: mdl-34289038
4.
Nomogram for predicting survival of patients with diffuse large B-cell lymphoma.
Ann Hematol
; 103(6): 2041-2050, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38411628
5.
A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan.
Ann Hematol
; 103(2): 475-488, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37695378
6.
Fulminant hepatitis in a hepatitis B surface antigen-positive patient with adult T-cell leukemia-lymphoma after mogamulizumab monotherapy.
Hepatol Res
; 2024 May 21.
Article
in English
| MEDLINE | ID: mdl-38770705
7.
Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3.
Jpn J Clin Oncol
; 2024 May 24.
Article
in English
| MEDLINE | ID: mdl-38794892
8.
Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs.
Haematologica
; 108(12): 3399-3408, 2023 12 01.
Article
in English
| MEDLINE | ID: mdl-37470160
9.
Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients.
Hematol Oncol
; 41(3): 424-433, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-36426594
10.
Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study.
Hematol Oncol
; 41(3): 442-452, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-36433829
11.
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
Ann Hematol
; 102(4): 863-876, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-36862168
12.
Two-year outcomes of tirabrutinib monotherapy in Waldenström's macroglobulinemia.
Cancer Sci
; 113(6): 2085-2096, 2022 Jun.
Article
in English
| MEDLINE | ID: mdl-35332633
13.
Clinicopathological significance of CD28 overexpression in adult T-cell leukemia/lymphoma.
Cancer Sci
; 113(1): 349-361, 2022 Jan.
Article
in English
| MEDLINE | ID: mdl-34738707
14.
Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.
Cancer Sci
; 113(12): 4267-4276, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36052883
15.
Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab.
Br J Haematol
; 196(3): 629-638, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34632569
16.
Feed-forward regulatory loop driven by IRF4 and NF-κB in adult T-cell leukemia/lymphoma.
Blood
; 135(12): 934-947, 2020 03 19.
Article
in English
| MEDLINE | ID: mdl-31972002
17.
Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.
Haematologica
; 107(10): 2418-2431, 2022 10 01.
Article
in English
| MEDLINE | ID: mdl-35417939
18.
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Haematologica
; 107(10): 2408-2417, 2022 10 01.
Article
in English
| MEDLINE | ID: mdl-35354247
19.
CCR7 alterations associated with inferior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.
Hematol Oncol
; 40(5): 876-884, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36043457
20.
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.
Ann Hematol
; 101(10): 2123-2137, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-35943588